Currently browsing: Community News

Assorted News from Last Week: Three things to know if your child is diagnosed with cancer. CNN Correspondent Rene Marsh tells the story of her pediatric cancer journey with her 9-month old son:  “It was worse than a nightmare because I couldn’t wake up from this.” Gilead Sciences has unveiled a new global pediatric drug development center in Ireland that will have 33 job openings by the end of 2022.   Upcoming Webinars, Online Opportunities, and Meetings: Join advocates from around the country for the 2022 Rally for Medical Research! The Hill Day will take place on Wednesday, September 14, with […]

Assorted News from Last Week: Childhood cancer survivors of certain racial and ethnic groups were prone to more hospitalizations for various conditions years down the road. Survivorship Matters Blog:  Recapturing the Dream NCI’s new Molecular Characterization Initiative (MCI) is expanding comprehensive molecular characterization of tumors to children, adolescents, and young adults (AYAs) with newly diagnosed soft tissue sarcomas receiving care at hospitals affiliated with the Children’s Oncology Group. Intratumoral infusion of an oncolytic virus offered safe and feasible results, along with encouraging efficacy, in pediatric patients with diffuse intrinsic pontine glioma (DIPG). Some children with a type of brain cancer called […]

Assorted News from Last Week: Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia’s paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer. Bridge therapy ahead of autologous stem cell transplantation (ASCT) consolidation may benefit certain high-risk neuroblastoma patients with residual disease following induction regimens, according to a multicenter retrospective study. Novartis announced the FDA has granted accelerated approval to the BRAF inhibitor dabrafenib (Tafinlar) combined with the MEK inhibitor trametinib […]

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. On the basis of extensive experience in recent years, most notably with mAbs, persisting with administering myeloablative chemotherapy as the standard to treat children with high risk neuroblastoma is not […]

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. CAC2 Supporting Organization Member Day One Biopharmaceuticals mid-stage data show an overall response rate of 64% and clinical benefit rate of 91% in the first 22 evaluable patients treated with […]

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. A combination of brentuximab vedotin (Adcetris) and chemotherapy was safe and effective in pediatric patients (up to age 21 years) with newly diagnosed high-risk Hodgkin lymphoma. Cancer in lymph nodes […]

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. On May 20, 2022, the Food and Drug Administration approved azacitidine (Vidaza, Celgene Corp.) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). From Forbes:  Young adults who have […]

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. On May 20, 2022, the Food and Drug Administration approved azacitidine (Vidaza, Celgene Corp.) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). Pediatric cancer survivorship lessons 42 years […]

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. Recently, CCDI launched the CCDI Data Catalog web application, part of the CCDI Data Ecosystem. Adolescent and young adult (AYA) cancer survivors have a significantly increased risk for developing a […]